Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 147 entries
Sorted by: Best Match Show Resources per page
Germline whole exome sequencing and large-scale replication identifies .

Oncotarget

Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP.
PMID: 28881617
Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01.

We analyzed whole exome sequencing data in germline DNA from 412 high grade serous ovarian cancer (HGSOC) cases from The Cancer Genome Atlas Project and identified 5,517 genes harboring a predicted deleterious germline coding mutation in at least one...

Cite
Dicks E, Song H, Ramus SJ, et al. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017;8(31):50930-50940doi: 10.18632/oncotarget.15871.
Dicks, E., Song, H., Ramus, S. J., Oudenhove, E. V., Tyrer, J. P., Intermaggio, M. P., Kar, S., Harrington, P., Bowtell, D. D., Group, A. S., Cicek, M. S., Cunningham, J. M., Fridley, B. L., Alsop, J., Jimenez-Linan, M., Piskorz, A., Goranova, T., Kent, E., Siddiqui, N., Paul, J., Crawford, R., Poblete, S., Lele, S., Sucheston-Campbell, L., Moysich, K. B., Sieh, W., McGuire, V., Lester, J., Odunsi, K., Whittemore, A. S., Bogdanova, N., Dürst, M., Hillemanns, P., Karlan, B. Y., Gentry-Maharaj, A., Menon, U., Tischkowitz, M., Levine, D., Brenton, J. D., Dörk, T., Goode, E. L., Gayther, S. A., & Pharoah, D. P. P. (2017). Germline whole exome sequencing and large-scale replication identifies . Oncotarget, 8(31), 50930-50940. https://doi.org/10.18632/oncotarget.15871
Dicks, Ed, et al. "Germline whole exome sequencing and large-scale replication identifies ." Oncotarget vol. 8,31 (2017): 50930-50940. doi: https://doi.org/10.18632/oncotarget.15871
Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01. PMID: 28881617; PMCID: PMC5584218.
Copy Download .nbib Format: NLM
Clinical validation of genetic variants associated with .

Oncotarget

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.
PMID: 29100455
Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS...

Cite
Fasching PA, Häberle L, Rack B, et al. Clinical validation of genetic variants associated with . Oncotarget. 2017;8(44):78133-78143doi: 10.18632/oncotarget.17726.
Fasching, P. A., Häberle, L., Rack, B., Li, L., Hein, A., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Ruebner, M., Jenkins, G., Fridley, B., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., & Wang, L. (2017). Clinical validation of genetic variants associated with . Oncotarget, 8(44), 78133-78143. https://doi.org/10.18632/oncotarget.17726
Fasching, Peter A, et al. "Clinical validation of genetic variants associated with ." Oncotarget vol. 8,44 (2017): 78133-78143. doi: https://doi.org/10.18632/oncotarget.17726
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Clinical validation of genetic variants associated with . Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. PMID: 29100455; PMCID: PMC5652844.
Copy Download .nbib Format: NLM
Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma.

Journal of translational medicine

Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, Bulur PA, Allred JB, Creagan ET, Ingle JN, Gastineau DA, Vuk-Pavlovic S.
PMID: 16911798
J Transl Med. 2006 Aug 15;4:35. doi: 10.1186/1479-5876-4-35.

BACKGROUND: Dendritic cells (DCs) have been used as vaccines in clinical trials of immunotherapy of cancer and other diseases. Nonetheless, progress towards the use of DCs in the clinic has been slow due in part to the absence of...

Cite
Markovic SN, Dietz AB, Greiner CW, et al. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med. 2006;4:35doi: 10.1186/1479-5876-4-35.
Markovic, S. N., Dietz, A. B., Greiner, C. W., Maas, M. L., Butler, G. W., Padley, D. J., Bulur, P. A., Allred, J. B., Creagan, E. T., Ingle, J. N., Gastineau, D. A., & Vuk-Pavlovic, S. (2006). Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. Journal of translational medicine, 435. https://doi.org/10.1186/1479-5876-4-35
Markovic, Svetomir N, et al. "Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma." Journal of translational medicine vol. 4 (2006): 35. doi: https://doi.org/10.1186/1479-5876-4-35
Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, Bulur PA, Allred JB, Creagan ET, Ingle JN, Gastineau DA, Vuk-Pavlovic S. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med. 2006 Aug 15;4:35. doi: 10.1186/1479-5876-4-35. PMID: 16911798; PMCID: PMC1570143.
Copy Download .nbib Format: NLM
Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer.

American journal of cancer research

Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV.
PMID: 22206049
Am J Cancer Res. 2012;2(1):104-15. Epub 2011 Nov 21.

PURPOSE: To determine the prognostic value of FOXO1, GATA3 and Annexin-1 expression in breast cancer.METHODS: Tissue microarray and individual paraffin tissue slides from 131 patients were used for the study. The association of FOXO1, GATA3 and Annexin-1 expression with...

Cite
Wu Y, Elshimali Y, Sarkissyan M, et al. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2011;2(1):104-15
Wu, Y., Elshimali, Y., Sarkissyan, M., Mohamed, H., Clayton, S., & Vadgama, J. V. (2012). Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. American journal of cancer research, 2(1), 104-15.
Wu, Yanyuan, et al. "Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer." American journal of cancer research vol. 2,1 (2012): 104-15.
Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2012;2(1):104-15. Epub 2011 Nov 21. PMID: 22206049; PMCID: PMC3236574.
Copy Download .nbib Format: NLM
The association of telomere length with colorectal cancer differs by the age of cancer onset.

Clinical and translational gastroenterology

Boardman LA, Litzelman K, Seo S, Johnson RA, Vanderboom RJ, Kimmel GW, Cunningham JM, Gangnon RE, Engelman CD, Riegert-Johnson DL, Potter J, Haile R, Buchanan D, Jenkins MA, Rider DN, Thibodeau SN, Petersen GM, Skinner HG.
PMID: 24598784
Clin Transl Gastroenterol. 2014 Mar 06;5:e52. doi: 10.1038/ctg.2014.3.

OBJECTIVES: Telomeres are nucleoprotein structures that cap the end of chromosomes and shorten with sequential cell divisions in normal aging. Short telomeres are also implicated in the incidence of many cancers, but the evidence is not conclusive for colorectal...

Cite
Boardman LA, Litzelman K, Seo S, et al. The association of telomere length with colorectal cancer differs by the age of cancer onset. Clin Transl Gastroenterol. 2014;5:e52doi: 10.1038/ctg.2014.3.
Boardman, L. A., Litzelman, K., Seo, S., Johnson, R. A., Vanderboom, R. J., Kimmel, G. W., Cunningham, J. M., Gangnon, R. E., Engelman, C. D., Riegert-Johnson, D. L., Potter, J., Haile, R., Buchanan, D., Jenkins, M. A., Rider, D. N., Thibodeau, S. N., Petersen, G. M., & Skinner, H. G. (2014). The association of telomere length with colorectal cancer differs by the age of cancer onset. Clinical and translational gastroenterology, 5e52. https://doi.org/10.1038/ctg.2014.3
Boardman, Lisa A, et al. "The association of telomere length with colorectal cancer differs by the age of cancer onset." Clinical and translational gastroenterology vol. 5 (2014): e52. doi: https://doi.org/10.1038/ctg.2014.3
Boardman LA, Litzelman K, Seo S, Johnson RA, Vanderboom RJ, Kimmel GW, Cunningham JM, Gangnon RE, Engelman CD, Riegert-Johnson DL, Potter J, Haile R, Buchanan D, Jenkins MA, Rider DN, Thibodeau SN, Petersen GM, Skinner HG. The association of telomere length with colorectal cancer differs by the age of cancer onset. Clin Transl Gastroenterol. 2014 Mar 06;5:e52. doi: 10.1038/ctg.2014.3. PMID: 24598784; PMCID: PMC3972691.
Copy Download .nbib Format: NLM
Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in .

Drug metabolism and disposition: the biological fate of chemicals

Devarajan S, Moon I, Ho MF, Larson NB, Neavin DR, Moyer AM, Black JL, Bielinski SJ, Scherer SE, Wang L, Weinshilboum RM, Reid JM.
PMID: 30745309
Drug Metab Dispos. 2019 Apr;47(4):425-435. doi: 10.1124/dmd.118.084269. Epub 2019 Feb 11.

No abstract available.

Cite
Devarajan S, Moon I, Ho MF, et al. Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in . Drug Metab Dispos. 2019;47(4):425-435doi: 10.1124/dmd.118.084269.
Devarajan, S., Moon, I., Ho, M. F., Larson, N. B., Neavin, D. R., Moyer, A. M., Black, J. L., Bielinski, S. J., Scherer, S. E., Wang, L., Weinshilboum, R. M., & Reid, J. M. (2019). Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in . Drug metabolism and disposition: the biological fate of chemicals, 47(4), 425-435. https://doi.org/10.1124/dmd.118.084269
Devarajan, Sandhya, et al. "Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in ." Drug metabolism and disposition: the biological fate of chemicals vol. 47,4 (2019): 425-435. doi: https://doi.org/10.1124/dmd.118.084269
Devarajan S, Moon I, Ho MF, Larson NB, Neavin DR, Moyer AM, Black JL, Bielinski SJ, Scherer SE, Wang L, Weinshilboum RM, Reid JM. Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in . Drug Metab Dispos. 2019 Apr;47(4):425-435. doi: 10.1124/dmd.118.084269. Epub 2019 Feb 11. PMID: 30745309; PMCID: PMC6423619.
Copy Download .nbib Format: NLM
The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup.

Gynecologic oncology

Warring SK, Borah B, Moriarty J, Gullerud R, Lemens MA, Destephano C, Sherman ME, Bakkum-Gamez JN.
PMID: 34756471
Gynecol Oncol. 2021 Oct 27; doi: 10.1016/j.ygyno.2021.10.079. Epub 2021 Oct 27.

OBJECTIVE: The evaluation of women with perimenopausal abnormal uterine bleeding (AUB) and postmenopausal bleeding (PMB) to detect endometrial cancer (EC) and its precursors is not standardized and can vary widely. Consequently, costs associated with the workup and management undoubtedly...

Cite
Warring SK, Borah B, Moriarty J, et al. The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup. Gynecol Oncol. 2021;doi: 10.1016/j.ygyno.2021.10.079.
Warring, S. K., Borah, B., Moriarty, J., Gullerud, R., Lemens, M. A., Destephano, C., Sherman, M. E., & Bakkum-Gamez, J. N. (2021). The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup. Gynecologic oncology, . https://doi.org/10.1016/j.ygyno.2021.10.079
Warring, Simrit K, et al. "The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup." Gynecologic oncology vol. (2021). doi: https://doi.org/10.1016/j.ygyno.2021.10.079
Warring SK, Borah B, Moriarty J, Gullerud R, Lemens MA, Destephano C, Sherman ME, Bakkum-Gamez JN. The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup. Gynecol Oncol. 2021 Oct 27; doi: 10.1016/j.ygyno.2021.10.079. Epub 2021 Oct 27. PMID: 34756471.
Copy Download .nbib Format: NLM
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy.

Blood cancer discovery

Kretzmer H, Biran A, Purroy N, Lemvigh CK, Clement K, Gruber M, Gu H, Rassenti L, Mohammad AW, Lesnick C, Slager SL, Braggio E, Shanafelt TD, Kay NE, Fernandes SM, Brown JR, Wang L, Li S, Livak KJ, Neuberg DS, Klages S, Timmermann B, Kipps TJ, Campo E, Gnirke A, Wu CJ, Meissner A.
PMID: 33604581
Blood Cancer Discov. 2021 Jan;2(1):54-69. doi: 10.1158/2643-3230.BCD-19-0058. Epub 2020 Dec 03.

Most human cancers converge to a deregulated methylome with reduced global levels and elevated methylation at select CpG islands. To investigate the emergence and dynamics of the cancer methylome, we characterized genome-wide DNA methylation in pre-neoplastic monoclonal B cell...

Cite
Kretzmer H, Biran A, Purroy N, et al. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2020;2(1):54-69doi: 10.1158/2643-3230.BCD-19-0058.
Kretzmer, H., Biran, A., Purroy, N., Lemvigh, C. K., Clement, K., Gruber, M., Gu, H., Rassenti, L., Mohammad, A. W., Lesnick, C., Slager, S. L., Braggio, E., Shanafelt, T. D., Kay, N. E., Fernandes, S. M., Brown, J. R., Wang, L., Li, S., Livak, K. J., Neuberg, D. S., Klages, S., Timmermann, B., Kipps, T. J., Campo, E., Gnirke, A., Wu, C. J., & Meissner, A. (2021). Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood cancer discovery, 2(1), 54-69. https://doi.org/10.1158/2643-3230.BCD-19-0058
Kretzmer, Helene, et al. "Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy." Blood cancer discovery vol. 2,1 (2021): 54-69. doi: https://doi.org/10.1158/2643-3230.BCD-19-0058
Kretzmer H, Biran A, Purroy N, Lemvigh CK, Clement K, Gruber M, Gu H, Rassenti L, Mohammad AW, Lesnick C, Slager SL, Braggio E, Shanafelt TD, Kay NE, Fernandes SM, Brown JR, Wang L, Li S, Livak KJ, Neuberg DS, Klages S, Timmermann B, Kipps TJ, Campo E, Gnirke A, Wu CJ, Meissner A. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 Jan;2(1):54-69. doi: 10.1158/2643-3230.BCD-19-0058. Epub 2020 Dec 03. PMID: 33604581; PMCID: PMC7888194.
Copy Download .nbib Format: NLM
Statistical Models in Clinical Studies.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Matsui S, Le-Rademacher J, Mandrekar SJ.
PMID: 33647505
J Thorac Oncol. 2021 May;16(5):734-739. doi: 10.1016/j.jtho.2021.02.021. Epub 2021 Feb 26.

Although statistical models serve as the foundation of data analysis in clinical studies, their interpretation requires sufficient understanding of the underlying statistical framework. Statistical modeling is inherently a difficult task because of the general lack of information of the...

Cite
Matsui S, Le-Rademacher J, Mandrekar SJ. Statistical Models in Clinical Studies. J Thorac Oncol. 2021;16(5):734-739doi: 10.1016/j.jtho.2021.02.021.
Matsui, S., Le-Rademacher, J., & Mandrekar, S. J. (2021). Statistical Models in Clinical Studies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16(5), 734-739. https://doi.org/10.1016/j.jtho.2021.02.021
Matsui, Shigeyuki, et al. "Statistical Models in Clinical Studies." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 16,5 (2021): 734-739. doi: https://doi.org/10.1016/j.jtho.2021.02.021
Matsui S, Le-Rademacher J, Mandrekar SJ. Statistical Models in Clinical Studies. J Thorac Oncol. 2021 May;16(5):734-739. doi: 10.1016/j.jtho.2021.02.021. Epub 2021 Feb 26. PMID: 33647505; PMCID: PMC8085106.
Copy Download .nbib Format: NLM
Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.

Endocrinology

Jayaraman S, Reid JM, Hawse JR, Goetz MP.
PMID: 34480554
Endocrinology. 2021 Dec 01;162(12). doi: 10.1210/endocr/bqab191.

The selective estrogen receptor (ER) modulator, tamoxifen, is the only endocrine agent with approvals for both the prevention and treatment of premenopausal and postmenopausal estrogen-receptor positive breast cancer as well as for the treatment of male breast cancer. Endoxifen,...

Cite
Jayaraman S, Reid JM, Hawse JR, et al. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology. 2021;162(12)doi: 10.1210/endocr/bqab191.
Jayaraman, S., Reid, J. M., Hawse, J. R., & Goetz, M. P. (2021). Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology, 162(12), . https://doi.org/10.1210/endocr/bqab191
Jayaraman, Swaathi, et al. "Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside." Endocrinology vol. 162,12 (2021). doi: https://doi.org/10.1210/endocr/bqab191
Jayaraman S, Reid JM, Hawse JR, Goetz MP. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology. 2021 Dec 01;162(12). doi: 10.1210/endocr/bqab191. PMID: 34480554.
Copy Download .nbib Format: NLM
Manifold medicine: A schema that expands treatment dimensionality.

Drug discovery today

Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H.
PMID: 34600126
Drug Discov Today. 2021 Sep 29; doi: 10.1016/j.drudis.2021.09.016. Epub 2021 Sep 29.

Drug discovery currently focuses on identifying new druggable targets and drug repurposing. Here, we illustrate a third domain of drug discovery: the dimensionality of treatment regimens. We formulate a new schema called 'Manifold Medicine', in which disease states are...

Cite
Ung CY, Weiskittel TM, Correia C, et al. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today. 2021;doi: 10.1016/j.drudis.2021.09.016.
Ung, C. Y., Weiskittel, T. M., Correia, C., Kaufmann, S. H., & Li, H. (2021). Manifold medicine: A schema that expands treatment dimensionality. Drug discovery today, . https://doi.org/10.1016/j.drudis.2021.09.016
Ung, Choong Yong, et al. "Manifold medicine: A schema that expands treatment dimensionality." Drug discovery today vol. (2021). doi: https://doi.org/10.1016/j.drudis.2021.09.016
Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today. 2021 Sep 29; doi: 10.1016/j.drudis.2021.09.016. Epub 2021 Sep 29. PMID: 34600126.
Copy Download .nbib Format: NLM
Severe Capecitabine Toxicity Associated With a Rare .

JCO precision oncology

Ly RC, Schmidt RE, Kiel PJ, Pratt VM, Schneider BP, Radovich M, Offer SM, Diasio RB, Skaar TC.
PMID: 32923881
JCO Precis Oncol. 2020 Jun 12;4. doi: 10.1200/PO.20.00067. eCollection 2020.

No abstract available.

Cite
Ly RC, Schmidt RE, Kiel PJ, et al. Severe Capecitabine Toxicity Associated With a Rare . JCO Precis Oncol. 2020;4doi: 10.1200/PO.20.00067.
Ly, R. C., Schmidt, R. E., Kiel, P. J., Pratt, V. M., Schneider, B. P., Radovich, M., Offer, S. M., Diasio, R. B., & Skaar, T. C. (2020). Severe Capecitabine Toxicity Associated With a Rare . JCO precision oncology, 4. https://doi.org/10.1200/PO.20.00067
Ly, Reynold C, et al. "Severe Capecitabine Toxicity Associated With a Rare ." JCO precision oncology vol. 4 (2020). doi: https://doi.org/10.1200/PO.20.00067
Ly RC, Schmidt RE, Kiel PJ, Pratt VM, Schneider BP, Radovich M, Offer SM, Diasio RB, Skaar TC. Severe Capecitabine Toxicity Associated With a Rare . JCO Precis Oncol. 2020 Jun 12;4. doi: 10.1200/PO.20.00067. eCollection 2020. PMID: 32923881; PMCID: PMC7446391.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 147 entries